Stock listing
Hamburg:HPHA Heidelberg Pharma AG Aktie
German listing (Hamburg) of Heidelberg Pharma AG · home listing Xetra:HPHA
Follow Heidelberg Pharma AG into a list and get an email when it puts out news.
Share price · HAM:HPHA
€2.01 EUR 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- €2.01 – €2.01 EURNov 20, 2026
- Market cap
- €159.0M EURAt the close on Nov 20, 2026 · price × 79.11M shares outstanding
- 52-week range
- €1.93 – €3.19 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €33 EURMedian day 0 shares · 56 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Xetra:HPHA · Home | €2.01 EUR | -0.05 (-2.4%) | 4,035 | €2.13 | €2.13 | €1.95 | €2.06 | Close on Nov 20, 2026 |
| LSE:0QW5 | €2.12 EUR | +0.06 (+2.9%) | 6 | €2.12 | €2.12 | €2.12 | €2.06 | Close on Nov 20, 2026 |
| Frankfurt:HPHA | €2.00 EUR | -0.01 (-0.5%) | — | €2.01 | €2.01 | €2.00 | €2.01 | Close on Nov 20, 2026 |
| Dusseldorf:HPHA | €1.925 EUR | -0.075 (-3.7%) | — | €2.00 | €2.00 | €1.925 | €2.00 | Close on Nov 20, 2026 |
| Hamburg:HPHA | €2.01 EUR | 0.00 (0.0%) | — | €2.01 | €2.01 | €2.01 | €2.01 | Close on Nov 20, 2026 |
| Munich:HPHA | €2.08 EUR | 0.00 (0.0%) | — | €2.08 | €2.08 | €2.08 | €2.08 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · HAM:HPHA · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €2.04 | +0.04 | +2.0% | €2.04 | €2.04 | €2.04 | 0 | |
| €2.00 | -0.01 | -0.5% | €2.00 | €2.00 | €2.00 | 0 | |
| €2.01 | -0.03 | -1.5% | €2.01 | €2.01 | €2.01 | 0 | |
| €2.04 | +0.045 | +2.3% | €2.04 | €2.04 | €2.04 | 0 | |
| €1.995 | -0.105 | -5.0% | €1.995 | €1.995 | €1.995 | 0 | |
| €2.10 | +0.01 | +0.5% | €2.10 | €2.10 | €2.10 | 0 | |
| €2.09 | 0.00 | 0.0% | €2.09 | €2.09 | €2.09 | 0 | |
| €2.09 | +0.05 | +2.5% | €2.09 | €2.09 | €2.09 | 0 | |
| €2.04 | -0.06 | -2.9% | €2.04 | €2.04 | €2.04 | 0 | |
| €2.10 | +0.17 | +8.8% | €2.10 | €2.10 | €2.10 | 0 | |
| €1.93 | -0.16 | -7.7% | €1.93 | €1.93 | €1.93 | 0 | |
| €2.09 | -0.05 | -2.3% | €2.09 | €2.09 | €2.09 | 0 | |
| €2.14 | +0.07 | +3.4% | €2.14 | €2.14 | €2.14 | 0 | |
| €2.07 | -0.08 | -3.7% | €2.07 | €2.07 | €2.07 | 0 | |
| €2.15 | -0.04 | -1.8% | €2.15 | €2.15 | €2.15 | 0 | |
| €2.19 | -0.01 | -0.5% | €2.19 | €2.19 | €2.19 | 0 | |
| €2.20 | +0.02 | +0.9% | €2.20 | €2.20 | €2.20 | 0 | |
| €2.18 | +0.05 | +2.3% | €2.18 | €2.18 | €2.18 | 0 | |
| €2.13 | -0.10 | -4.5% | €2.13 | €2.13 | €2.13 | 0 | |
| €2.23 | 0.00 | 0.0% | €2.23 | €2.23 | €2.23 | 0 | |
| €2.23 | -0.02 | -0.9% | €2.23 | €2.23 | €2.23 | 0 | |
| €2.25 | -0.02 | -0.9% | €2.25 | €2.25 | €2.25 | 0 | |
| €2.27 | -0.04 | -1.7% | €2.27 | €2.27 | €2.27 | 0 | |
| €2.31 | +0.02 | +0.9% | €2.31 | €2.31 | €2.31 | 0 | |
| €2.29 | 0.00 | 0.0% | €2.29 | €2.29 | €2.29 | 0 | |
| €2.29 | +0.02 | +0.9% | €2.29 | €2.29 | €2.29 | 0 | |
| €2.27 | -0.13 | -5.4% | €2.27 | €2.27 | €2.27 | 0 | |
| €2.40 | +0.14 | +6.2% | €2.40 | €2.40 | €2.40 | 0 | |
| €2.26 | -0.24 | -9.6% | €2.26 | €2.26 | €2.26 | 0 | |
| €2.50 | +0.02 | +0.8% | €2.50 | €2.50 | €2.50 | 0 | |
| €2.48 | +0.01 | +0.4% | €2.48 | €2.48 | €2.48 | 0 | |
| €2.47 | -0.01 | -0.4% | €2.47 | €2.47 | €2.47 | 0 | |
| €2.48 | +0.09 | +3.8% | €2.48 | €2.48 | €2.48 | 0 | |
| €2.39 | -0.06 | -2.4% | €2.39 | €2.39 | €2.39 | 0 | |
| €2.45 | +0.09 | +3.8% | €2.45 | €2.45 | €2.45 | 0 | |
| €2.36 | -0.15 | -6.0% | €2.36 | €2.36 | €2.36 | 0 | |
| €2.51 | +0.03 | +1.2% | €2.51 | €2.51 | €2.51 | 0 | |
| €2.48 | 0.00 | 0.0% | €2.48 | €2.48 | €2.48 | 0 | |
| €2.48 | +0.03 | +1.2% | €2.48 | €2.48 | €2.48 | 0 | |
| €2.45 | +0.06 | +2.5% | €2.45 | €2.45 | €2.45 | 0 | |
| €2.39 | -0.05 | -2.0% | €2.39 | €2.39 | €2.39 | 0 | |
| €2.44 | -0.01 | -0.4% | €2.44 | €2.44 | €2.44 | 0 | |
| €2.45 | 0.00 | 0.0% | €2.45 | €2.45 | €2.45 | 0 | |
| €2.45 | -0.01 | -0.4% | €2.45 | €2.45 | €2.45 | 0 | |
| €2.46 | 0.00 | 0.0% | €2.46 | €2.46 | €2.46 | 0 | |
| €2.46 | +0.01 | +0.4% | €2.46 | €2.46 | €2.46 | 0 | |
| €2.45 | +0.01 | +0.4% | €2.45 | €2.45 | €2.45 | 0 | |
| €2.44 | -0.01 | -0.4% | €2.44 | €2.44 | €2.44 | 0 | |
| €2.45 | -0.08 | -3.2% | €2.45 | €2.45 | €2.45 | 0 | |
| €2.53 | +0.04 | +1.6% | €2.53 | €2.53 | €2.53 | 0 | |
| €2.49 | -0.01 | -0.4% | €2.49 | €2.49 | €2.49 | 0 | |
| €2.50 | +0.04 | +1.6% | €2.47 | €2.50 | €2.47 | 750 | |
| €2.46 | -0.02 | -0.8% | €2.46 | €2.46 | €2.46 | 0 | |
| €2.48 | 0.00 | 0.0% | €2.48 | €2.48 | €2.48 | 0 | |
| €2.48 | +0.02 | +0.8% | €2.48 | €2.48 | €2.48 | 0 | |
| €2.46 | +0.02 | +0.8% | €2.46 | €2.46 | €2.46 | 0 | |
| €2.44 | -0.03 | -1.2% | €2.44 | €2.44 | €2.44 | 0 |
Splits
1 split · HAM:HPHA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-4 | Consolidation |
- Ticker
- Hamburg:HPHA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Hamburg
- Currency
- EUR
What changed lately
Latest news release · Nov 4, 2026
Heidelberg Pharma to Present New Clinical Data on its ATAC Candidates at the ASH Annual Meeting 2026
Latest deck · Mar 26, 2026
FY2025 Earnings Presentation
Earnings · 19 slides
Latest news
Heidelberg Pharma to Present New Clinical Data on its ATAC Candidates at the ASH Annual Meeting 2026
Nov 4, 2026
Closed €2.00 (-0.5%) on Nov 5, 2026
Heidelberg Pharma Reports on the First Nine Months of Financial Year 2026
Oct 15, 2026
Closed €2.20 (+0.9%) on Oct 15, 2026
Heidelberg Pharma Presented New Clinical Data for Lead ATAC Candidate Pamlectabart Tismanitin at IMS Annual Meeting 2026
Sep 24, 2026
Closed €2.47 (-0.4%) on Sep 24, 2026
Heidelberg Pharma to Present New Clinical Data on Lead ATAC Candidate Pamlectabart Tismanitin at International Myeloma Society Annual Meeting 2026
Sep 7, 2026
Closed €2.46 (0.0%) on Sep 7, 2026
Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates
Aug 28, 2026
Closed €2.49 (-0.4%) on Aug 28, 2026
Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China
Aug 26, 2026
Closed €2.50 (+1.6%) on Aug 27, 2026
Heidelberg Pharma Reports on First Half-Year 2026 and the Positive Course of Business
Jul 15, 2026
Closed €2.46 (-5.0%) on Jul 15, 2026
Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2026
Jun 23, 2026
Closed €2.53 (-0.8%) on Jun 23, 2026
Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2026
Apr 29, 2026
Closed €2.79 (+0.7%) on Apr 29, 2026
Heidelberg Pharma Announces Change in Executive Board
Apr 17, 2026
Closed €2.72 (0.0%) on Apr 17, 2026
Heidelberg Pharma AG on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 17 in all · newest Nov 4, 2026 · oldest 2025
- Decks
- 25 decks · latest Mar 26, 2026
Where Heidelberg Pharma AG is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Xetra:HPHA · Home listing | Xetra | Germany | EUR |
| gettex:HPHA | gettex | Germany | EUR |
| Tradegate:HPHA | Tradegate | Germany | EUR |
| LS Exchange:A11QVV | LS Exchange | Germany | EUR |
| LSE:0QW5 | LSE | United Kingdom | EUR |
| Lang & Schwarz:A11QVV | Lang & Schwarz | Germany | EUR |
| Frankfurt:HPHA | Frankfurt | Germany | EUR |
| Stuttgart:HPHA | Stuttgart | Germany | EUR |
| Dusseldorf:HPHA | Dusseldorf | Germany | EUR |
| Hamburg:HPHA · This page | Hamburg | Germany | EUR |
| Munich:HPHA | Munich | Germany | EUR |
| Aquis:HPHAD | Aquis | United Kingdom | EUR |
| Aquis:HPHAD | Aquis | United Kingdom | EUR |
| BX Swiss:HPHA | BX Swiss | Switzerland | CHF |
| Turquoise:HPHAD | Turquoise | United Kingdom | EUR |
| VIE:HPHA | Vienna | Austria | EUR |
Valuation
EV/sales 8.0× against a median of 128×: 3rd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Aug 31, 2026 · price Nov 20, 2026
- Enterprise value
- €74.49M EUR
- P/E
- Loss
- EV/sales
- 8.0×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 79.5%
- Operating margin
- −331.5%
- Net margin
- −320.9%
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Heidelberg Pharma AG · XETR:HPHA | US$103.2M | US$81.75M | n/a | 8.0× | n/a | n/a | −320.9% | n/a | n/a |
| Nykode Therapeutics ASA · OSL:NYKD | US$107.0M | US$62.24M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| JW (Cayman) Therapeutics Co. Ltd. · HKEX:2126 | US$105.3M | US$84.72M | n/a | 2.0× | n/a | 1.6× | −195.8% | 0.6× | n/a |
| Genelux Corporation · NASDAQ:GNLX | US$104.3M | US$93.85M | n/a | 11,732× | n/a | 11.4× | n/a | 0.0× | 1.52 |
| Cardiol Therapeutics Inc. Class A · TSX:CRDL | US$103.4M | US$83.06M | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.45 |
| Foghorn Therapeutics Inc. · NASDAQ:FHTX | US$103.1M | −US$9.22M | 10.9× | −0.1× | −2.5× | n/a | 8.4% | n/a | 1.57 |
| Vivani Medical, Inc. · NASDAQ:VANI | US$102.8M | US$88.24M | n/a | n/a | n/a | 7.8× | n/a | 0.0× | 0.93 |
| Paradigm Biopharmaceuticals Ltd. · ASX:PAR | US$101.6M | US$96.33M | n/a | 1,816× | n/a | 44.2× | n/a | 2.2× | n/a |
| Innate Pharma SA Class A · EURONEXT:IPH | US$101.5M | US$111.7M | n/a | 36.5× | n/a | n/a | n/a | n/a | n/a |
| BRIM Biotechnology, Inc. · TWSE:6885 | US$100.3M | US$70.71M | n/a | 220× | n/a | 2.1× | n/a | 0.0× | n/a |
| Minerva Neurosciences, Inc · NASDAQ:NERV | US$99.67M | US$22.73M | n/a | n/a | n/a | n/a | n/a | n/a | 1.68 |
| Median of the others | US$103.0M | US$83.89M | 10.9× | 128× | −2.5× | 5.4× | −93.7% | 0.0× | 1.52 |
Forecasts
Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 6.75 EUR · Analysts' mean
- EPS, year to Nov 2026
- -0.52 · 1 analyst
- Revenue, year to Nov 2026
- 10M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Dongzhou Jeffery Liu | Chief Executive Officer |
| Peter Willinger | Chief Financial Officer |
| Jörg Kemkowski | Chief Operating Officer |
| Sylvia Wimmer | Senior Director Corporate Communications |
| George Badescu | Chief Business Officer |
| Yan Xia | Director of ADC Research Center |
Board
| Director | Role |
|---|---|
| Karl Benedikt Biesinger | Chairman |
| Jack Yefei Ling | Deputy Director of Finance International Business Department |
| Klaus Schollmeier | |
| Mathias Hothum | Deputy Chairman |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2026 | Mar 26, 2026 | +3.1% |
| Q4 2025 | Jan 28, 2026 | −5.7% |
| Q3 2025 | Oct 9, 2025 | +0.6% |
| Q2 2025 | Jul 10, 2025 · Before open | +3.3% |
| Q1 2025 | Apr 24, 2025 · Before open | +3.3% |
| Q4 2024 | Jan 29, 2025 | −1.2% |
| Q3 2024 | Oct 10, 2024 · Before open | +4.1% |
| Q2 2024 | Jul 12, 2024 · Before open | +0.4% |
| Q1 2024 | Apr 25, 2024 · Before open | −0.3% |
| Q3 2023 | Oct 12, 2023 · Before open | −0.3% |
All 18 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Jul 13, 2023 · Before open | +0.6% |
| Q1 2023 | Apr 13, 2023 · Before open | −2.1% |
| Q3 2022 | Oct 13, 2022 · After close | +0.8% |
| Q2 2022 | Jul 12, 2022 · Before open | 0.0% |
| Q1 2022 | Mar 24, 2022 | +3.1% |
| Quarter to Aug 31, 2021 | Oct 7, 2021 | +9.1% |
| Quarter to May 31, 2021 | Jul 8, 2021 | −0.7% |
| Quarter to Feb 28, 2021 | Apr 20, 2021 | −4.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| FY2025 Earnings Presentation | Earnings | 19 slides | Mar 26, 2026 |
| Hamburger Investorentage 2026 | Conference | 25 slides | Feb 5, 2026 |
| Investor Presentation (January 2026) | Investor deck | 19 slides | January 2026 |
| 16th World ADC Conference San Diego (November 2025) | Conference | 25 slides | November 2025 |
| Eigenkapitalforum 2025 | Conference | 26 slides | November 2025 |
| Corporate Update (September 2025) | Corporate update | 10 slides | Sep 25, 2025 |
| International Myeloma Society 22nd Annual Meeting & Exhibition 2025 | Conference | 16 slides | Sep 20, 2025 |
| Investor Presentation (September 2025) | Investor deck | 44 slides | September 2025 |
| Investor Presentation (August 2025) | Investor deck | 43 slides | August 2025 |
| Investor Presentation (June 2025) | Investor deck | 41 slides | June 2025 |
All 25 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Bio€quity 2025 | Conference | 14 slides | May 13, 2025 |
| German Spring Conference 2025 | Conference | 25 slides | May 12, 2025 |
| FY2024 Earnings Presentation | Earnings | 24 slides | Mar 24, 2025 |
| Investor Presentation (February 2025) | Investor deck | 42 slides | February 2025 |
| International Myeloma Society 21st Annual Meeting & Exhibition 2024 | Conference | 13 slides | Sep 25, 2024 |
| FY2023 Earnings Presentation | Earnings | 21 slides | Mar 25, 2024 |
| Inv€$tival Showcase 2023 | Conference | 21 slides | Nov 13, 2023 |
| Deutsche Biotechnologietage 2023 | Conference | 20 slides | Mar 28, 2023 |
| Inv€$tival Showcase 2022 | Conference | 19 slides | Nov 14, 2022 |
| FY2021 Earnings Presentation | Earnings | 25 slides | Mar 24, 2022 |
| FY2020 Earnings Presentation | Earnings | 28 slides | Mar 25, 2021 |
| German Equity Forum / EKF 2020 | Conference | 26 slides | November 2020 |
| Investor Presentation (August 2019) | Investor deck | 32 slides | August 2019 |
| Investor Presentation (November 2018) | Investor deck | 31 slides | Nov 19, 2018 |
| Investor Presentation (July 2018) | Investor deck | 31 slides | July 2018 |
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.46M | 6.85M | 9.86M | 18.5M | 2.90M | 8.49M | 7.31M | 3.67M | 1.90M | 1.36M |
| Cost of revenue | 2.64M | 1.78M | 3.25M | 4.68M | 4.71M | 5.60M | 3.74M | 2.21M | 956.7K | 809.1K |
| Gross profit | -1.19M | 5.07M | 6.61M | 13.8M | -1.81M | 2.89M | 3.57M | 1.46M | 943.3K | 552.9K |
| Research and development | 38.8M | 21.8M | 28.1M | 26.4M | 18.8M | 18.3M | 10.9M | 10.7M | 9.32M | 6.12M |
| Selling, general and administrative | 7.61M | 6.74M | 5.25M | 4.82M | 3.99M | 3.58M | 3.14M | 2.97M | 2.75M | 1.95M |
| Operating income | -47.4M | -20.7M | -21.2M | -17.2M | -25.1M | -18.6M | -10.4M | -11.7M | -10.8M | -6.36M |
| Depreciation and amortization | 2.82M | 871.2K | 879.0K | 756.6K | 802.9K | 733.9K | 546.6K | 369.0K | 406.2K | 279.9K |
| EBITDA | -44.6M | -19.8M | -20.3M | -16.4M | -24.3M | -17.8M | -9.82M | -11.3M | -10.3M | -6.08M |
| Interest expense | 4.91K | 141.5K | 761.6K | 840.0K | 494.0K | 13.6K | 220.9K | 0 | 218.0K | 20.0K |
| Income before tax | -41.2M | -19.4M | -20.3M | -17.8M | -26.1M | -18.4M | -10.1M | -11.7M | -11.0M | -6.38M |
| Income tax | 1.05M | 1 | 1.92M | 494.5K | 4.56K | 5.01K | 570.5K | 417.4K | 9.45K | |
| Net income | -42.3M | -19.4M | -20.3M | -19.7M | -26.1M | -18.4M | -10.1M | -11.7M | -11.0M | -6.39M |
| Earnings per share, basic | -0.91 | -0.42 | -0.44 | -0.53 | -0.80 | -0.61 | -0.36 | -0.41 | -0.76 | -0.22 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 15.0M | 29.4M | 43.4M | 81.3M | 6.14M | 4.98M | 9.88M | 19.4M | 30.4M | 4.57M |
| Short-term investments | -30.0K | -34.9K | -34.9K | -25.3K | -35.3K | -15.0K | ||||
| Receivables | 2.35M | 5.95M | 2.32M | 1.45M | 1.02M | 1.23M | 1.41M | 400.9K | 263.5K | 225.2K |
| Inventory | 10.6M | 11.8M | 10.5M | 4.59M | 745.9K | 229.8K | 237.7K | 177.6K | 178.0K | 190.2K |
| Current assets | 28.3M | 47.6M | 56.6M | 87.9M | 9.01M | 7.52M | 11.6M | 20.3M | 31.2M | 4.99M |
| Property, plant and equipment | 3.67M | 3.11M | 2.43M | 1.95M | 1.30M | 1.27M | ||||
| Goodwill | 6.11M | 6.11M | 6.11M | 6.11M | 6.11M | 6.11M | 6.11M | 6.11M | 6.11M | 6.11M |
| Total assets | 38.1M | 60.7M | 70.4M | 100.6M | 21.7M | 19.6M | 23.0M | 31.2M | 41.5M | 15.2M |
| Accounts payable | 7.16M | 5.55M | 7.88M | 3.05M | 903.0K | 2.81M | 1.01M | 405.5K | 1.50M | 132.1K |
| Current liabilities | 11.2M | 8.00M | 19.8M | 27.9M | 14.9M | 6.63M | 6.46M | 5.31M | 4.46M | 5.48M |
| Total debt | 1.16M | 22.0M | 5.83M | 16.0M | 10.6M | 202.7K | 3.75M | |||
| Total liabilities | 49.1M | 29.9M | 21.0M | 33.9M | 15.0M | 6.73M | 6.70M | 5.31M | 4.47M | 5.49M |
| Shareholders' equity | -10.9M | 30.9M | 49.3M | 66.6M | 6.70M | 12.9M | 16.3M | 25.9M | 37.0M | 9.76M |
| Shares outstanding | 46.7M | 46.6M | 46.6M | 37.2M | 32.5M | 29.9M | 28.2M | 28.2M | 14.4M | 28.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -31.6M | -29.6M | -33.7M | -8.86M | -26.6M | -17.9M | -8.56M | -9.98M | -7.94M | -6.53M |
| Capital spending | -128.7K | -456.0K | -959.9K | -612.9K | -1.39M | -1.43M | -963.2K | -1.00M | -416.1K | -537.9K |
| Free cash flow | -31.7M | -30.0M | -34.6M | -9.48M | -28.0M | -19.3M | -9.52M | -11.0M | -8.36M | -7.07M |
| Cash from investing | -135.0K | -449.1K | 5.85M | -597.6K | -1.40M | -1.29M | -975.8K | -1.00M | -416.1K | -537.9K |
| Cash from financing | 18.3M | 16.1M | -10.1M | 84.0M | 29.2M | 14.3M | -1 | 14.3M | 34.2M | 10.3M |
| Share buybacks | -755.7K | |||||||||
| Change in cash | -14.4M | -14.0M | -37.9M | 75.2M | 1.16M | -4.90M | -9.56M | -10.9M | 25.8M | 3.27M |
Cap table
Built by 6ix from Heidelberg Pharma AG’s releases
- Common shares
- 46,784,317
- Fully diluted
- 46,784,317
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 46,784,317 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 46,784,317 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Dongzhou Jeffery Liu | Chief Executive Officer · Since at least Oct 15, 2026 |
| George Badescu | Chief Business Officer · Since at least Nov 5, 2026 |
| Jack Yefei Ling | Deputy Director of Finance International Business Department · Since at least Jul 15, 2026 |
| Jörg Kemkowski | Chief Operating Officer · Since at least Nov 5, 2026 |
| Karl Benedikt Biesinger | Chairman · Since at least Apr 17, 2026 |
| Klaus Schollmeier | Director · Since at least Mar 26, 2026 |
| Mathias Hothum | Deputy Chairman · Since at least Mar 26, 2026 |
| Peter Willinger | Chief Financial Officer · Since at least Oct 15, 2026 |
| Sylvia Wimmer | Senior Director Corporate Communications · Since at least Oct 15, 2026 |
| Yan Xia | Director of ADC Research Center · Since at least Mar 26, 2026 |
Log in to ask 6ix AI your own questions about Heidelberg Pharma AG.